Last reviewed · How we verify
CM-AT
CM-AT is a serine protease that breaks down extracellular proteins to improve protein digestion and absorption in patients with autism spectrum disorder.
CM-AT is a serine protease that breaks down extracellular proteins to improve protein digestion and absorption in patients with autism spectrum disorder. Used for Autism spectrum disorder with gastrointestinal dysfunction.
At a glance
| Generic name | CM-AT |
|---|---|
| Also known as | 900mg CM-AT (pancreatic enzyme concentrate, 720mg |
| Sponsor | Curemark |
| Drug class | Serine protease |
| Target | Dietary proteins / extracellular proteolysis |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | Phase 3 |
Mechanism of action
CM-AT is designed to enhance the digestive breakdown of dietary proteins by providing enzymatic activity in the gastrointestinal tract. The rationale is based on the hypothesis that incomplete protein digestion may contribute to gastrointestinal dysfunction and behavioral symptoms in autism spectrum disorder. By improving protein digestion, the drug aims to reduce gastrointestinal symptoms and potentially improve behavioral outcomes.
Approved indications
- Autism spectrum disorder with gastrointestinal dysfunction
Common side effects
- Gastrointestinal symptoms
- Abdominal discomfort
Key clinical trials
- Effect of a Driving Pressure Adjustment Procedure for High-Frequency Jet Ventilation in Patients Undergoing Tumor Thermal Ablation in Interventional Radiology (NA)
- Modified Tumor-free Techniques Operation to Cervical Cancer (NA)
- IASTM and Vibration Effects on Pain, Functionality, and Kinesiophobia in Lumbar Disc Herniation (NA)
- A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany
- Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) (PHASE2)
- Cortical Plasticity of the Tactile Mirror System in Borderline Personality Disorder (NA)
- Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer (PHASE3)
- Indocyanine Green Fluorescence Angiography (ICG-FA) in Revisional Bariatric Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CM-AT CI brief — competitive landscape report
- CM-AT updates RSS · CI watch RSS
- Curemark portfolio CI